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ABSTRACT
Background: This paper discusses national programs implemented in
India, Pakistan, Malaysia, and Philippines to generate and apply evidence
in making informed policy decisions on the approval, pricing, reimburse-
ment and ﬁnancing of medicines, diagnostics, and medical devices.
Approval: In all countries, the Ministries of Health are generally
responsible for approval of health technologies through various agencies
like the Central Drugs Standard Control Organisation in India, Bureau
of Food and Drugs for medicines and Bureau of Health Devices
and Technology for medical devices in the Philippines, the National
Pharmaceutical Control Bureau, Health Technology Assessment Unit
and Medical Device Bureau in Malaysia, and the Drug Control Orga-
nization in Pakistan. Product dossiers are evaluated while taking
decisions.
Pricing Control: India has a strong price control mechanism through the
National Pharmaceutical Pricing Authority. In the Philippines, the Essen-
tial Drug Price Monitoring System monitors prices of 37 essential drugs
monthly from all drugstore outlets nationwide. In Malaysia and Pakistan
registration pricing of new drugs is negotiated/ﬁxed by the government
with the vendor.
Reimbursement: A mix of social, voluntary private and community-based
health insurance plans are available in India while the Philippine Health
Insurance Corporation is responsible for reimbursement of drugs and
medical devices in the Philippines. In Malaysia no formal reimbursement
system is being practiced, and in Pakistan the government reimburses
medical claims of its employees.
Financing: In both India and the Philippines the bulk of health expendi-
ture is out of pocket while the government pays for 20% and 28%
respectively in both countries. The public health care services in Malaysia
are heavily subsidized by the government with minimum fee being charged
to the public. The government of Pakistan gives free medicines to its
citizens at the public health facilities.
Conclusions: In the region under discussion, one of the priority areas that
the different regulatory agencies would beneﬁt from is human resource
development to facilitate the process of evidence based assessment of
health technologies. Higher budgetary allocation and stronger legislation
is also needed along with interagency and international coordination and
cooperation to harmonize.
Keywords: drug approval, drug ﬁnancing, drugs reimbursement, pricing.
Background
The Asia-Paciﬁc region has some of the fastest-growing econo-
mies in the world, especially with respect to pharmaceuticals.
The health-care systems in this area are very dynamic, and there
is also a major diversity among its people, political systems,
wealth, and state of development. Australia was the ﬁrst country
in this region where data related to pharmacoeconomics (PE) and
outcomes research (OR) were made mandatory for health-care
policy decisions. In recent years, PE and OR have emerged as
important for decision-making in health policy in various coun-
tries of the Asia-Paciﬁc region including Taiwan, Thailand, South
Korea, China, Japan, and Singapore.
India, Pakistan, Malaysia, and Philippines have, albeit slower
than their other Asian counterparts, implemented some systems
to generate and apply evidence in making informed policy deci-
sions on the approval, pricing, reimbursement, and ﬁnancing of
medicines, diagnostics, and medical devices. Against the back-
ground of a changing canvas, this article will describe the
national processes in place in these countries to generate and
apply evidence in making informed policy decisions on the
approval, pricing policies, reimbursement, and ﬁnancing policies
of medicines, diagnostics, and medical devices.
The methods used while writing this article included a review
of various ofﬁcial documents (including Web sites) such as legis-
lations, government issuances, guidelines, and other ofﬁcial
documents that portray the process and status of evidence-based
decisions on medical technologies. If thought necessary, inter-
views were also conducted with key resource persons to get
expert insights and ﬁrsthand data on the research subject. Each
author contributed information pertinent to their country.
Approval
India
Approval of new drugs for marketing is the function of the
Central Drugs Standard Control Organisation (CDSCO) (http://
cdsco.nic.in/; last accessed January 29, 2009) headed by the
Drugs Controller General (India) (DCGI). The CDSCO is
attached to the ofﬁce of the Director General of Health Services
in the Ministry of Health and Family Welfare, and the DCGI is a
statutory authority under the Act and has port ofﬁces, zonal
ofﬁces, and drug testing laboratories functioning under him.
Apart from this, the Central government (through the CDSCO)
also grants permission to conduct clinical trials before granting
marketing authorization. The CDSCO is also responsible for the
registration and control of the quality of imported drugs; laying
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down regulatory measures and amendment of Acts and Rules;
laying down standards for drugs, cosmetics, diagnostics, and
devices; and updating the Indian Pharmacopoeia.
Part X-A of The Drugs and Cosmetics Act, 1940 and The
Drugs and Cosmetics Rules 1945 (available at http://cdsco.nic.in/
html/Copy%20of%201.%20D&CAct121.pdf; last accessed
February 3, 2009) describes the requirements for approval of a
new drug for marketing in the country. A new drug is deﬁned in
Rule 122 as a new substance of chemical, biological, or biotech-
nological origin in bulk or as a prepared dosage form, a drug
already approved by the licensing authority that is now proposed
to be marketed with modiﬁed or new claims, a ﬁxed-dose com-
bination of two or more drugs, individually approved earlier for
certain claims, which are proposed to be combined in a ﬁxed
ratio, and all vaccines. Before approval, basic information on
chemistry, physicochemical information, complete monograph
speciﬁcations, and data on the formulation including quality
control data, animal pharmacology and toxicology and human/
clinical pharmacology are reviewed.
India has moved into a product patent regime in 2005,
becoming compliant with the Trade Related Aspects of Intellec-
tual Property Rights provisions of the World Trade Organisation
(WTO). In a series of amendments to the Indian Patents Act,
1970, the latest and the crucial amendment to the Act was made
in March 2005, effective April 1, 2005 [1]. This has spurred new
drug development activities in the country, and till date more
than 60 molecules have reached the clinical development stage.
Although the licensing authority remains the CDSCO (the DCGI
being the statutory authority), the detailed dossiers on the pre-
clinical data on the new molecule are evaluated by the Investi-
gational New Drug (IND) Committee set up for this purpose.
The evidence submitted by the company is evaluated, and
initially, permissions are given to conduct clinical trials, and after
phase III results are submitted and permission for marketing is
given.
Philippines
In the Philippines, the basic infrastructure and mechanisms
operate in pursuance of the country’s major health-related legis-
lations, i.e., the Foods, Drugs, Devices and Cosmetics Act [2], the
Generics Act of 1988 [3], the Price Act [4], the National Health
Insurance Act of 1995 [5], and other pertinent laws and govern-
ment issuances. Within this context, the mandates to make deci-
sions over health technologies are delegated among various
ofﬁces across the health sector bureaucracy.
The Bureau of Food and Drugs (BFAD) [2,6] regulates the
production, import, export, sale, and distribution of drugs in the
country as well as monitors the quality of products. BFAD is
responsible for the issuance of the license to operate to drug
manufacturers, traders of drug products, distributors, and drug
outlets and for the registration of products such as processed
foods, drugs, medical devices, in vitro diagnostic reagents, cos-
metics, and household hazardous substances.
Evaluation of applications by BFAD for registration of phar-
maceutical products involves examination of product dossiers
containing technical speciﬁcations of raw materials and ﬁnished
products as well as certiﬁcates of analysis. These are veriﬁed for
consistency with ofﬁcial references such as the US, British, Japan,
European and Philippine Pharmacopoeias and Martindale: The
Extra Pharmacopeia. If there are no speciﬁc references and no
known speciﬁcations of the product, BFAD requires the company
to submit validation reports or a certiﬁcate of pharmaceutical
product from the country of origin or the country where the
product is freely sold.
Clinical investigation data (phases I–III) and protocol for
local clinical trial are required for new drugs. Products with
additional dosage or dosage strength, and those with new indi-
cation(s) or route of administration, require phase III clinical
trials. Phase IV clinical studies may be asked from products
applying for renewal of registration. The protocols for such trials
are approved by BFAD.
BFAD works with the following committees for the approval/
registration of drugs: 1) an ad hoc committee activated when
decision conﬂicts arise; 2) the Vaccine and Biological Working
Group/Immunization Safety Surveillance System Review Board;
and 3) the Product Recall Committee.
To give a separate focus on medical devices, an executive
order (issued in 1999) created the Bureau of Health Devices
Technology to specialize on the regulation of medical devices,
health-related devices, radiation devices, and radiation facilities
(medical and nonmedical) [7].
Malaysia
Various agencies such as the National Pharmaceutical Control
Bureau (NPCB), Health Technology Assessment (HTA) unit, and
Medical Device Bureau (MDB) within the Malaysian Ministry of
Health (MMOH) are responsible for regulating medical tech-
nologies, including for assessing new medical technologies and to
make recommendations for their approval or otherwise.
The Drug Control Authority (DCA) consists of a 10-member
committee (Director-General of Health, Director of Pharmaceu-
tical Services, Director of NPCB, consultant physician in the
public service, pharmacist in the public service, three persons
from any local universities with expertise in pharmaceutical sci-
ences, and two fully registered medical practitioners). The NPCB
is responsible for drug regulation and is the best established
organization with laws already in place. It is the executive arm of
the DCA.
The function of the NPCB includes product evaluation,
product assessment through laboratory testing, Good Manufac-
turing Practice inspections, processing product certiﬁcate and
licenses, postmarketing surveillance, and monitoring of adverse
drug reaction.
A mandatory registration scheme was implemented in 1984,
and “Control of Drugs and Cosmetic Regulations 1984” was
gazetted to support this function. Together with this regulation,
the “Sales of Drug Act 1952,” the “Poisons Act 1952,” and the
“Medicines (Advertisement and Sale) Act 1952,” the Pharma-
ceutical Services Division of the Ministry of Health (MOH)
began to regulate the importation, manufacturing, sale, and
advertisement of drugs in Malaysia.
The Health Technology Assessment in Health Care Section
(HTA Malaysia) was established in August 1995 under the
Medical Programme, Ministry of Health Malaysia and has been
a World Health Organization (WHO) Collaborating Centre for
Evidence Based Practice since July 2004. The unit functions to
provide input for technology-related policies, give advice, and
provide HTA information to health-care providers and the
public, and to coordinate the formulation and implementation of
clinical practice guidelines (CPGs) [8].
The HTA unit is the secretariat to the Health Technology
Assessment & Clinical Practice Guidelines (HTA & CPG)
Council. The HTA & CPG Council is chaired by the Director-
General of Health with members representing the Deputy
Director-Generals, the state or hospital director, the nursing pro-
fession, the Academy of Medicine, universities (medical facul-
ties), the Malaysian Medical Association, and the Association of
Private Hospitals. The council sets policies and priorities related
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to health technology assessment and reviews, approves, dissemi-
nates, and implements CPGs and formulated technology-related
policies.
The HTA unit is also the secretariat to the Technical Advisory
Committee (TAC), which is a division under the HTA & CPG
Council. The TAC is chaired by the Director of Medical Devel-
opment Division, whose membership includes directors of the
following divisions: Medical Practice, Engineering, Pharmacy,
Planning and Development, Family Health Development, and
Head of Health Systems Research Institute. Through the imple-
mentation of the Private Healthcare Facilities & Services Act
1998, the MOH regulates the types, quanta, and locations of
technologies and services.
The HTA unit produces two types of reports depending on
the urgency of the request. A comprehensive HTA report takes 8
to 16 months to prepare and is sent to external reviewers. The
report is prepared based on the analysis, interpretation, and
synthesis of scientiﬁc research and/or technology assessment con-
ducted by other organizations and also would incorporate any
Malaysian data if available. A Technology Review Report is a
brief report prepared in response to an urgent health technology
information request. This report is prepared within 1 to 2
months, has no external reviewer, and is restricted to only
reviews and analysis of pertinent literature, expert opinion, and
regulatory status. An HTA report is initiated by a request made
by completing the “Request for Health Technology Assessment”
form, which is available online (http://www.moh.gov.my). The
HTA unit receives health technology assessment topics from
various organizations within the MOH for prioritization every 2
years. The TAC prioritizes the technologies to be assessed and
presents it to the HTA & CPG Council. Priority setting is con-
ducted so that the request for assessments is in line with the
policies and objectives of the organization. Each request is
assessed against several priority setting criteria that take into
account factors such as the objective of the assessment, capital
and recurrent costs, effects on other services and infrastructure,
availability of competing technologies, signiﬁcance of technol-
ogy, and its level of usage.
To date (June 2006), 42 HTA reports (in-depth assessment)
have been prepared and 114 Technical Reviews (rapid assess-
ment) have been conducted [9]. The impact of the health tech-
nology assessment program can be seen in areas such as in policy
and planning services/facilities, purchasing decision, and regula-
tion of medical devices. Examples of impact on the formulation
of MOH policy include introduction of new services and modi-
ﬁcations of existing services (commencement of home nursing
services), introduction of new proven technology (stroke reha-
bilitation services), introduction of national screening program
(routine ultrasound screening for high-risk pregnancy), replace-
ment of older technology (low-temperature sterilization), and
discontinuing of ineffective practices (elimination of routine chest
x-rays in routine medical examinations). The impact on purchas-
ing decision involved the choice of cost-effective options involv-
ing stereotactic radiosurgery (linear accelerator vs. cyber knife vs.
gamma knife) and medical management of benign prostatic
hypertrophy. With the HTA unit recommendation, it is manda-
tory for medical devices costing more than RM200,000
(US$57,000) to undergo Health Technology Assessment before it
is purchased for MOH facilities. In view of the newly proposed
Medical Devices Act & Regulation (which is in preparation),
Health Technology Assessment will be carried out for speciﬁc
medical devices before its registration.
The MDB was formed in September 2005 to function as a
regulatory agency for medical devices with the aim of addressing
public health and safety issues related to medical device trade and
industry. The role of the MDB includes registering medical
devices, issuing licenses to manufacturers, distributors, import-
ers, and exporters, inspecting facilities, monitoring medical
devices already in the market, monitoring the operation and
usage of medical devices including disposal, and also the drafting
of law and standards. The MDB can only achieve its aim and
perform its regulatory functions effectively through comprehen-
sive legislation. In view of this, the Medical Device Bill 2008,
prepared to support this regulatory function, and is currently
with the Attorney General’s Chamber, and is scheduled to be
tabled in the next parliament sitting. Preparation of the relevant
subsidiary legislations has also been initiated, and the ﬁrst draft
of Medical Devices (Premarket) Regulation has also been com-
pleted [10].
The DCA evaluated a total of 27, 907 applications for
product registration in 2006, of which 234 were rejected. Of
those approved 1.7% was prescription drugs, 2.3% over-the-
counter products, 5.6% traditional medicines and 90.4%
cosmetics [11].
Pakistan
The Drug Act of 1976 provides a legal framework for the import,
export, manufacturing, storage, distribution, and sale of medi-
cines (human and veterinary) in Pakistan. The function and
authorities mentioned in the drug Act have been distributed
between the federal and provincial governments. Except for sur-
veillance, storage, sale, and issues related to postmarketing of
medicines, the rest of the functions are the responsibility of the
federal government [12].
The Drug Control Organization (DCO) of Pakistan has two
critical roles: licensing new pharmaceutical and drug companies
and drug registration. On the analogy of WHO essential medi-
cines, the DCO maintains an essential medicine list (EML) con-
taining 452 medicines. Nevertheless, there is no legal mechanism
to ensure the availability of essential medicines of the EML.
The licensing of new pharmaceutical units is carried out by the
Central Licensing Board (CLB) of the DCO headed by the Addi-
tional Secretary of the MOH. The CLB relies on Good Manufac-
turing practices standards for license of manufacturing or import
of medicines. At present there are 454 licensed pharmaceutical
units in the country, while only 27 are multinational [12].
Drug approval is generally on the basis of efﬁcacy, quality




Statutory price control on drugs was ﬁrst introduced in India in
1962, initially including a list of 18 “lifesaving drugs” which were
considered by the Tariff Commission to decide the cost structure
of these lifesaving drugs. The formal Drug Price Control Order
was introduced by the government of India in 1970 to keep the
prices of drugs at affordable limits to the consumers and at the
same time ensure that manufacturers received reasonable returns.
The Order captured 347 bulk drugs in various categories under
its net. Under this act the minimum percentage of proﬁt margin
was deﬁned depending on the category the drug belonged to.
Further, the manufacturers were permitted to charge a maximum
amount of postmanufacturing expenses [1]. The number of
drugs under price control came down to 142 in 1987, and
the Drug Price Control Order of 1995 pruned the list to just 74
drugs (http://www.nppaindia.nic.in/drug_price95/txt1.html; last
accessed February 15, 2009).
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The government set up the National Pharmaceutical Pricing
Authority (NPPA) on August 29, 1997 (http://www.nppaindia.
nic.in/index1eng.html; last accessed February 15, 2009). This is
an independent body of experts consisting of a chairperson in the
status of the secretary to the government of India, members
having expertise in the ﬁeld of pharmaceuticals, economics, and
cost accountancy, and a member secretary in the status of joint
secretary/additional secretary to the government of India. The
NPPA was entrusted with the task of price ﬁxation revision and
other related matters such as updating the list of drugs under
price control by inclusion and exclusion on the basis of the
established criteria/guidelines.
The NPPA also monitors the prices of decontrolled drugs and
formulations and oversees the implementation of the provisions
of the Drugs (Prices Control) Order. In addition to these func-
tions, the Authority also monitors the availability of drugs, iden-
tiﬁes shortages, and takes remedial steps; collects and maintains
data on production, exports, and imports, market share of indi-
vidual companies, proﬁtability of companies, etc., for bulk drugs
and formulations; and undertakes and/or sponsors relevant
studies in respect of pricing of drugs/pharmaceuticals. It is the
NPPA that advices the government on changes/revisions in the
drug policy, as well as assists the government in parliamentary
matters relating to the drug pricing.
As part of its monitoring activity, the NPPA monitors and
analyses month-wise price movements of nonscheduled medi-
cines based on ORG-IMS reports. The prices of these formu-
lations are ﬁxed/determined by manufacturers themselves
depending on various factors like the cost of production, market
competition, the company’s proﬁtability status, etc. The NPPA
monitors the prices of nonscheduled formulations through
various methods like scrutiny of price lists submitted by manu-
facturers, analysis of monthly “Retail store audit reports” pub-
lished by ORG-IMS, and complaints/references received from
ofﬁcial and nonofﬁcial sources. Studies are also commissioned
when deemed necessary by the NPPA from voluntary organiza-
tions [13].
Philippines
The Price Act of 1992, among other provisions, reinforces the
authority of the Philippine president to impose a price ceiling on
any basic necessity or prime commodity, upon the recommenda-
tion of the Department of Health (DOH) or the Price Coordi-
nating Council, in cases of calamity, emergency, illegal price
manipulation, or whenever the prevailing prices rise to unrea-
sonable levels [4].
In compliance with the Price Act, the DOH has authorized
National Drug Policy-Compliance Ofﬁcers and BFAD through
the Essential Drug Price Monitoring System (EDPMS) to monitor
the prices of 37 essential drugs monthly from all drugstore
outlets nationwide [14]. These drugs are identiﬁed as essential
drugs based on leading causes of morbidity and mortality and the
Philippine National Drug Formulary (PNDF). With the institu-
tionalization of the EDPMS, more speciﬁc guidelines for drug
selection have been issued. The list of EDPMS drugs will now be
based on accepted therapies for the prevalent diseases, cost-
effectiveness, and cost minimization data from the National Drug
Policy Program (NDPP) and the National Formulary Committee
(NFC), Philippine Health Insurance Corporation (PhilHealth)-
adopted CPGs, and PhilHealth claims reimbursement. Resource
speakers from other DOH units, the industry, the academia, the
health sector, and other relevant government agencies may also
be consulted.
An Order issued to institutionalize and strengthen the
EDPMS mandates the DOH to prepare reports to determine the
price levels and inventory of essential drug prices classiﬁed as
basic necessities and identiﬁes price manipulation on essential
drugs. An Essential Drug Price Monitoring Oversight Committee
reviews all activities undertaken to implement the Generics Law
and the Price Act and recommends to the Secretary of Health
price ceilings of essential drugs. The NDPP, in collaboration with
the NFC and PhilHealth, determines which medicines are classi-
ﬁed as essential drugs classiﬁed as basic necessities that must be
monitored nationwide [15].
This year, the “Universally Accessible Cheaper and Quality
Medicines Act of 2008” [16], which aims to bring down the cost
of medicines in the country, was signed into law reinforcing the
president’s authority to impose the price ceiling for certain drugs.
Monthly data collection of drug prices is decentralized to
local units of BFAD. Data sources include pharmacies of leading
government and private hospitals in terms of bed capacity and
leading private drugstore chain in terms of sales, covering only
those outlets located in the capital city or province in the region
concerned [17]. This information on drug prices as well as levels
of inventory will be a part of the evaluation of the overall
performance of retail outlets and wholesalers and will be a rel-
evant factor in the issuance and renewal of their licenses to
operate. Annually, the drug prices would be compared with
international prices.
A joint effort of PhilHealth and the DOH led to the publica-
tion of a range of drug prices of top 185 drugs collected from a
sample of drug points of sales across the country (Drug Price
Reference Index [DPRI]). This aimed to make the public aware of
the appropriate price of medicines and achieve price transpar-
ency as an initial step to empower consumers and improve access
to medicines.
PhilHealth is also developing a scheme to reduce and control
its own cost for drugs by utilizing a DPRI as basis for reimburse-
ment of medicines. The DPRI is a list of reference prices imple-
mented as the ceiling price for the reimbursement of certain drug
preparations. PhilHealth will only reimburse up to the DPRI
price. Otherwise, the exact amount of the drugs will be paid.
The DPRI is hoped to promote rational and fair drug pricing,
rational use of drugs, and drug price transparency.
Malaysia
The prices of new technologies are negotiated through a central
purchasing system between the MMOH and the vendor for the
public sector. Nevertheless, in the private sector there is no
formal pricing control mechanism.
Pakistan
The Drug Registration Board is responsible for the registration
and pricing of new medicines. The Drug Act of 1976 is vague
about the price policy except in asking for ﬁxing a price that is
reasonable and affordable by the public. From 1976 to 1993 the
medicines pricing was carried out on a case-to-case basis. In the
mid-1990s, the government did some innovations for price ﬁxa-
tion, but later this was discontinued. Since 2002 the prices of all
medicines have been ﬁxed independently. In 2008, the government
formulated a Price Advisory Committee, which is expected to con-
trol the prices of either the top 100 most commonly used mol-
ecules or the essential medicines, recommended by theWHO [18].
Reimbursement
India
Social security for health care is not new to the Indian
ethos—exempliﬁed at its simplest in the form of a collection of a
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fund by villagers to support a household with a sick patient.
Nevertheless, health insurance was introduced formally only in
1912 when the ﬁrst Insurance Act (the current version of this Act
is dated 1938) was passed. In 1972 the insurance industry was
nationalized and 107 private insurance companies were brought
under the umbrella of the General Insurance Corporation. When
the Insurance Regulatory and Development Act was enacted in
1999, private and foreign agencies were allowed to enter the
market.
Even today, only about 3% to 5% of Indians are covered
under any form of health insurance [19]. The Indian health
insurance scenario is a mix of mandatory social health insurance,
voluntary private health insurance, and community-based health
insurance. This includes those covered under the Central Gov-
ernment Health Scheme (CGHS; 4 million beneﬁciaries), the
Railways Health Scheme (1.2 million), and the Employees’ State
Insurance Scheme (0.3 million), all examples of social health
insurance. Premiums collected by private health insurance agen-
cies are a meager 0.3% of the total health expenditure, further
emphasizing the lack of general acceptance of the concept risk
pooling [20].
Enacted in 1948, the Employees’ State Insurance Act was the
ﬁrst major legislation on social security in India. The scheme
applies to power-using factories employing 10 persons or more
and to nonpower and other speciﬁed establishments employing
20 persons or more, with employees’ earnings up to Rs 7500 per
month being covered, along with their dependents. The current
coverage stands at more than 8,400,000 employees and
35,300,000 beneﬁciaries across 22 States and Union Territories.
The beneﬁt package is quite comprehensive in its coverage of
health-related expenses and includes the cost of medicines. The
Employees’ State Insurance Scheme is ﬁnanced by a three-
way contribution from employers, employees, and the state
government.
The CGHS was started by the Ministry of Health and Family
Welfare, Government of India in 1954 with the objective of
providing comprehensive medical care facilities to central gov-
ernment employees, their family members, and pensioners and
other select individuals with over 43,00,000 beneﬁciaries. This
scheme allows beneﬁciaries reimbursement of health-care
expenses, and a “Package Rate” has been ﬁxed at approved
hospitals across the country that includes, apart from the lump-
sum cost of inpatient treatment/day care/diagnostic procedure,
the cost of medicines. The amount that a beneﬁciary is entitled to
depends on his or her basic pay/pension. No formal system is
described for the inclusion or exclusion of medicines in this list.
Private insurance (through approximately 12 general insur-
ance companies and 25 third party administrators) covers about
11,200,000 individuals with almost 90% enrolled with the four
public sector insurance companies. Nevertheless, private insur-
ance is not the answer for India’s objective of equity, efﬁciency,
and quality in health because it tends to select for the afﬂuent
classes, covering the healthiest and the wealthiest, resulting in
limited social gain [19].
To provide ﬁnancial risk cover to the poor, the government of
India announced a Universal Health Insurance Scheme in 2003.
Under this scheme, health care was provided for families below
the poverty line for relatively small premiums (subsidized heavily
by the government). Unfortunately, the coverage has been
poor—perhaps because the public sector companies who were
required to implement this scheme ﬁnd it to be potentially loss-
making and do not invest in marketing it, resulting in very low
levels of awareness. An important reason for failure has also been
that the poor ﬁnd it difﬁcult to pay the premium for a potential
future beneﬁt, foregoing current needs.
The National Rural Health Mission was launched in 2005,
seeking to provide accessible, affordable, and quality health care
to the vulnerable section of the rural population. Health insur-
ance is promoted through this scheme in an attempt to mitigate
the distress of households in seeking health care by reducing
out-of-pocket expenditures (it is reported that three-fourths of
the total out-of-pocket health expenditure is spent on drugs)
through risk pooling. Importantly, the government has promised
to subsidize the premiums for such insurance schemes so that
patients below the poverty line are beneﬁted.
Philippines
The Philippines National Health Insurance Act requires that
reimbursement of claims for drugs is based on the latest edition
of the PNDF unless explicit exception is made by PhilHealth
[21]. In pursuance of this cause, PhilHealth established the HTA
Committee in 1999 to develop reimbursement policies on
medical claims based on quality measures, i.e., cost-effectiveness
of tests and treatments. The HTA Committee, consisting of an
Expert Panel drawn from various medical ﬁelds, conducts drug
assessments, evaluates the safety and effectiveness of medical
devices and medical and surgical procedures, and appraises and
disseminates CPGs developed by local medical societies.
The NFC is the functional unit that formulates the PNDF.
Decisions over drugs by the NFC are crucial because government
entities are mandated to procure only drugs listed in the PNDF.
Also, all drugs listed in the PNDF are reimbursable under the
National Health Insurance Program [22,23]. The NFC uses the
Formulary Selection Algorithm as a step-by-step evidence-based
drug selection process to formulate the PNDF [24,25]. Proposals
for the inclusion or exclusion of drugs are deliberated and sub-
sequently decided upon using a consultative and participatory
process with different panels of experts from medical schools, the
Philippine Medical Association, specialty and subspecialty soci-
eties, government and private hospitals, pharmaceutical compa-
nies, and other stakeholders [26].
In addition, PhilHealth maintains a Positive List (consisting
of 36 medicines) which is a compilation of non-PNDF drugs
reimbursed by PhilHealth. For making this list, data are obtained
on safety and cost-effectiveness from the results of clinical trials,
postmarketing surveillance studies, adverse drug reaction reports
from local and international sources, and local retail drug costs.
Only systematic reviews of randomized controlled trials (RCTs)
and individual RCTs are included by the HTA Committee in the
drug assessments. Nonrandomized comparative clinical trials are
considered if there are no RCTs or if there is an ethical reason for
not conducting RCTs. If the drug is found to be more cost-
effective and poses no additional risk compared with the stan-
dard drug, then it is recommended for inclusion in the Positive
List provided that it is used for the conditions for which it was
found effective. In 2000, PhilHealth included drugs in the Posi-
tive List that were lifted from three adopted CPGs: community-
acquired pneumonia, hypertension, and urinary tract infection.
CPGs that PhilHealth adopts undergo critical appraisal that
involves a systematic search for local and international guide-
lines. These guidelines are screened for relevance to the needs of
PhilHealth. To conﬁrm the validity of methods, PhilHealth uti-
lizes the AGREE Instrument and an appraisal checklist developed
in-house. From the appraised guidelines, PhilHealth extracts rec-
ommendations on disease assessment, laboratory tests, drug
treatments, and admission policies, which are then evaluated for
applicability to local settings. Finally, PhilHealth ensures that
drugs included in the policy recommendations are in the national
formulary.
S22 Thatte et al.
Apart from evaluating drugs, PhilHealth also conducts
evidence-based health technology assessments on devices, diag-
nostics, and medical and surgical procedures. Results of these
evaluations serve as inputs into the development of beneﬁt pack-
ages for health services.
Malaysia
There is no reimbursement system in the public sector because
health services are very heavily subsidized by the MMOH, with
a minimum fee being charged to the public. For the poor and
disabled, these facilities are made available for free.
Pakistan
All registered medicines by the DCO are eligible for marketing
and reimbursement, although the government only reimburses
expenditure on medicines incurred on treatment in public sector
health facilities. State and Para state organizations such as the
Pakistan Armed Forces, Pakistan Railway, and Pakistan Televi-
sion Corporation, etc., either have their own health-care system
or reimburse medical claims of their employees [27]. Neverthe-
less, the pricing and reimbursement mechanism of these organi-
zations is not documented. In the North West Frontier province,
the provincial health department selects medicines through com-
petitive bidding on the basis of quality and price for the pur-
chases in the public sector health institution in the province.
Financing
India
Financing for drugs occurs through several sources, including
tax-based public sector, that comprise local (2.2%), state (14.4%),
and central governments (7.2%), in addition to numerous autono-
mous public sector bodies; private sector including the not-for-
proﬁt sector, organizing ﬁnance for their employees either directly
or through insurance; households through out-of-pocket expen-
ditures (68.8%); insurance schemes; and through external grants
and loans (2%). In India there is a clear urban–rural, rich–poor
divide. Thus, afﬂuent, urban populations and thoseworking in the
organized sector covered under some form of social security such
as the Employees State Insurance Scheme orCGHShave unlimited
access to medical services. The rural population and those
working in the unorganized sector have only the tax-based public
facilities to depend on for free or subsidized care, and private
facilities depending on their ability to pay [28].
The estimated health expenditure in India for the year 2001
to 2002 was approximately Rs 108,732 crore, accounting for
4.8% of the gross domestic product (GDP) expenditure, with the
share for drugs being about 12%, although this ranges from a
poor of 2% in Punjab state to 15% in Tamil Nadu and 17% in
Kerala [1].
Although reimbursement schemes are not common in India,
poor patients have access to several free health-care programs in
the country run by the government under which drugs are pro-
vided free. One of the largest schemes is the “Rashtriya Arogya
Nidhi” (erstwhile National Illness Assistance Fund) (set up in
1997) where funds have been made available to assist patients
below the poverty line coming to All India Institute of Medical
Science or other central government hospitals for treatment of
their speciﬁc life-threatening illness. Grants are given to the hos-
pitals to be used on an as needed basis. There is a Technical
Committee to advise the Managing Committee on technical
matters such as nature of illness to be covered for assistance
under the scheme and other ancillary issues. Thus, relevant to
this article, the following items are paid for: pacemakers, cardiac
and other stents, vascular shunts and drugs including anticancer
chemotherapy, immunosuppressive drugs, antituberculosis (TB)
drugs, anti-D, antihemophilic globulin, erythropoietin, blood
and blood products/plasma for patients of burns.
The government also runs several national programs that
provide free drugs for poor patients, including the National AIDS
Control Program, National Leprosy Eradication Program (http://
www.whoindia.org/EN/Section3/Section122_1215.htm;
accessed February 15, 2009), National Vector Borne Diseases
Control Programme (http://www.nvbdcp.gov.in/aboutus.html;
accessed February 15, 2009), and National Tuberculosis Control
Program (http://www.tbcindia.org/; accessed February 15, 2009).
Philippines
The Philippines spends only about 3.3% of its GDP for health,
with per capita health expenditure at ~$45 (in 2005) (http://
www.nscb.gov.ph/stats/pnha/2005/healthexp.asp; accessed Feb-
ruary 25, 2009). Only 28% of the health expenditure is provided
for by the government (16% from the national government and
12% from the local government). The bulk of the expenses on
health (48%) are paid by the patient. Social health insurance
provided by PhilHealth covers about 10% (http://www.
nscb.gov.ph/stats/pnha/2005/sources.asp; accessed February 25,
2009).
The national coverage of PhilHealth currently stands at 76%
or roughly 69 million Filipinos. In 2007, 32% of the reimburse-
ments by PhilHealth were made for drugs and medicines. These
are mostly for inpatient beneﬁts and comprise about 5% of the
total national expenditure for drugs and medicines.
Medical care, including medicines and vaccines, are provided
free for the high-burden and highly endemic diseases in the
Philippines. These include TB, malaria, schistosomiasis, ﬁlariasis,
rabies, HIV/AIDS, and some common primary health problems.
These are covered by the DOH and delivered at the Primary
Healthcare Centers and Barangay Health Units. The National
Center for Disease Prevention and Control formulates these ver-
tical programs, whereas the Center for Health Development
leads the monitoring and utilization.
Malaysia
The public health-care services in Malaysia are heavily subsidized
by the government, with minimum fee being charged to the
public. Drugs that are made available through the public health-
care system are controlled through the Ministry of Health Drug
List, which was ﬁrst introduced in 1983, and contains 1403
products. The selection of drugs to be included in the formulary
is based on their safety, efﬁcacy, quality, and budget implications.
This list is reviewed periodically by the Drug List Review Panel
chaired by the Deputy Director-General of Health (Research &
Technical Support) assisted by 16 working committees consisting
of senior consultants and pharmacists from the MOH on various
categories of specialties. The drug review is based on clinical
advantage, best and current treatment options, current and pre-
vious usage, prescribing pattern, approved dosage and indica-
tion, and cost of treatment. The panel meets twice or thrice a year
to consider proposals for additions, deletions, alteration of
dosage form/formulation/indication/category of prescriber for
the MOH Drug Formulary. From 2000 until 2006, a total of 254
drugs have been deleted from the Drug List and 199 drugs added
[29].
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Pakistan
The government of Pakistan gives free medical care (including
medicines) to its citizens at the public health facilities. In addition,
there are special Zakat funds (meant for the poor) at the disposal
of the tertiary and teaching hospital administration. Besides, all
federal vertical programs for the prevention and control of major
communicable diseases such as TB, hepatitis,malaria, leprosy, and
common primary health problems providemedicines and vaccines
for treatment and prevention free of any cost.
For the formal sector of Pakistan, medical charges including
medicines are usually reimbursed by some system. Nevertheless,
these groups are only a fraction of the total population. The rest
of the population rely on private out-of-pocket ﬁnancing for
health care, mainly doctor fees and medicines.
Although health care in Pakistan is mainly a provincial
subject, issues related to drugs, medicines, and health insurance
overlap between provinces and the federation [30]. Pakistan
spends about 2.5% of its GDP on health care, and in 2005 the
per capita health expenditure was US$15. Nevertheless, in terms
of ﬁnance and delivery, the private sector provides almost two-
thirds of health care to the population [31].
Conclusions
In this article we described the national processes in place in
India, Philippines, Malaysia, and Pakistan to generate and apply
evidence in making informed policy decisions on the approval,
pricing policies, reimbursement, and ﬁnancing policies of medi-
cines, diagnostics, and medical devices.
Regulation of drugs and medical devices requires adequately
trained technical individuals who are capable of applying evi-
dence in policy decisions. Additionally, they should be familiar
with related policies and procedures. In the region under discus-
sion, one of the priority areas that the different regulatory agen-
cies would beneﬁt from is human resource development to
facilitate this process. Support from the government in terms of
higher budgetary allocation and stronger legislation is also
needed to strengthen the regulatory functions of the concerned
agencies. Interagency coordination should also be reinforced to
maximize the use of limited resources. An area of concern across
the region is the paucity of regulation of devices.
It is also necessary to promote intercountry cooperation to
allow the sharing of best practices as well as to harmonize
practices across the region. Because complementary medicines
(including strong local traditional medicines like Ayurveda in
India) are very popular there is a need to promote the concepts of
PE and OR in these areas as well.
Business models to sustain the operations of these regulatory
agencies must be explored. Nevertheless, this should be done in
a manner that will maintain the integrity and credibility of the
processes. Lastly, there should be a policy on disclosure of con-
ﬂict of interest among concerned committees and personnel.
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